
Pfizer to Pay $5.4 Billion for Global Blood Therapeutics
Pfizer is paying $5.4 billion to acquire Global Blood Therapeutics (GBT), a drugmaker specialized in treating blood disorders. It is one of several deals the company has inked recently to offset dwindling sales from its vaccine and therapeutics for Covid-19.






























































